Details of the Drug Formulations

General Information of Drug (ID: DMCS6M5)

• Drug Name: Voxelotor Drug Info
• Synonyms: Hemoglobin Modulators-1; 1446321-46-5; UNII-3ZO554A4Q8; GBT 440; 3ZO554A4Q8; 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Voxelotor [USAN]; SCHEMBL15065529; Voxelotor(GBT440, GTx011); GTX-011; GBT-440; MolPort-044-830-677; FWCVZAQENIZVMY-UHFFFAOYSA-N; AKOS030526545; ZINC145969085; CS-5317; HY-18681; DA-44587; S

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Approved	[1]

• Cross-matching ID:
  PubChem CID: 71602803
  CAS Number: 1446321-46-5
  TTD ID: D09RII
  INTEDE ID: DR1713
  ACDINA ID: D01530

Full List of Drug Formulations Containing This Drug

Voxelotor 500 mg tablet

Company	Formulation ID	FDA Description
Global Blood Therapeutics	F23323	Colloidal Silicon Dioxide; Croscarmellose Sodium; Magnesium Stearate; Microcrystalline Cellulose; Sodium Lauryl Sulfate; Polyethylene Glycol 3350; Polyvinyl Alcohol; Talc; Titanium Dioxide; Yellow Iron Oxide

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019